Spinogenix Awarded $3 Million NIH Grant to Support Continued Development of SPG302, the First Synaptic Regenerative Therapeutic for Alzheimer’s Disease
Treatment Could Help Restore Brain Functions Lost in Many Neurogenerative DisordersSAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Spinogenix, Inc.,...